Jiangxi Institute of Biological Products Inc. (“Jiangxi Bio”) has launched its Global Offering ahead of a Main Board debut on the Stock Exchange of Hong Kong, aiming to raise as much as HK$473.22 million through the sale of up to 36.23 million H-shares (subject to an over-allotment option).

The share sale is split into a Hong Kong Public Offering of 3.62 million shares (10% of the deal, subject to reallocation) and an International Offering of 32.61 million shares (90%, subject to reallocation and a 15% over-allotment option of 5.44 million shares). Each H-share carries a nominal value of RMB1.00.

The indicative price range is HK$9.33–HK$13.06. Investors applying through the Hong Kong tranche are required to pay the top-end price of HK$13.06 per share on application, inclusive of 1.0% brokerage, a 0.0027% SFC transaction levy, a 0.00015% AFRC levy and a 0.00565% Stock Exchange trading fee. Should pricing be fixed below the maximum, excess funds will be refunded.

Key dates: • Offer period: 9:00 a.m. Monday, 22 June 2026 to 12:00 noon Thursday, 25 June 2026 • Expected price determination: by 12:00 noon Friday, 26 June 2026 • Allocation and pricing results: by 11:00 p.m. Monday, 29 June 2026 • First trading day: 9:00 a.m. Tuesday, 30 June 2026 (stock code 6915) • Stabilisation window: up to Saturday, 25 July 2026

Settlement will be executed through CCASS, with H-shares traded in board lots of 500. China International Capital Corporation Hong Kong Securities Limited will act as Stabilizing Manager and may undertake price-stabilisation activities within 30 days of the close of the Hong Kong Public Offering. The Hong Kong Underwriting Agreement allows termination up to 8:00 a.m. on the listing date under specified circumstances.